Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy

Details for Australian Patent Application No. 2006227879 (hide)

Owner Pfizer Products Inc.

Inventors Gomez-Navarro, Jesus

Agent Shelston IP

Pub. Number AU-A-2006227879

PCT Pub. Number WO2006/101691

Priority 60/664,364 23.03.05 US; 60/711,707 26.08.05 US

Filing date 3 March 2006

Wipo publication date 28 September 2006

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 38/09 (2006.01) Medicinal preparations containing peptides

A61P 35/00 (2006.01) Antineoplastic agents

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

20 September 2007 PCT application entered the National Phase

  PCT publication WO2006/101691 Priority application(s): WO2006/101691

25 February 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006227880-Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer

2006227864-Single-track stacking panel covering for an architectural opening